By Ilan Zipkin
Staff Writer

Cor Therapeutics Inc. had hoped to enter the market with its Integrilin peptide platelet inhibitor in an indication that is not yet served by other GPIIb/IIIa platelet inhibitors, namely early emergency room treatment of unstable angina patients. Instead, the FDA's Cardiovascular and Renal Drugs Advisory Committee last week recommended that Integrilin be approved for use in conjunction with percutaneous transluminal coronary angioplasty (PTCA), where it will have to compete directly with Centocor Inc.'s ReoPro platelet inhibiting antibody.